Literature DB >> 11578269

Investigation of coronary artery bypass grafting for a patient with myelodysplastic syndrome.

Y Miyagi1, S Yamauchi, S Suzuki, A Kitagawa, Y Masaki, M Gomibuchi, S Tanaka.   

Abstract

A 79-year-old male with unstable angina, who had myelodysplastic syndrome (MDS), was treated with coronary artery bypass grafting (CABG). MDS causes refractory anemia accompanied by various degrees of granulocytopenia and thrombocytopenia. Pancytopenia caused by MDS may complicate patients with major infections and bleeding during cardiac surgery. There were very few patients with MDS who had undergone open-heart surgery. Three case studies, including this study, had reported successful cases of CABG in patients with MDS and the analogous diseases of MDS. We used granulocyte colony-stimulating factor (G-CSF), red blood cells (RBCs) and platelets transfusions in peri-operative state. We did not need a large amount of transfusion of RBCs and platelets in intra-operative and postoperative states. We had prevented major bleeding and severe wound infections in the acute postoperative state.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11578269

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  3 in total

1.  Successful replacement of aortic root with valve-sparing technique and proximal arch in a patient with myelodysplastic syndrome.

Authors:  Tomomi Hasegawa; Takuro Tsukube; Tomonori Higuma; Yutaka Okita
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-07

2.  Successful aortic valve replacement in severe pancytopenia related to myelodysplastic syndrome.

Authors:  Kazuhiro Kurisu; Yoshie Ochiai; Takashi Kajiwara; Ryuji Tominaga
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-02

3.  Minimally invasive mitral valve repair via right mini-thoracotomy in patient with myelodysplastic syndrome.

Authors:  Takura Taguchi; Hiroyuki Nishi; Kimihiro Kurose; Kohei Horikawa; Go Kanazawa; Toshiki Takahashi
Journal:  J Cardiothorac Surg       Date:  2018-05-18       Impact factor: 1.637

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.